QualityStocks Stock Newsletters Archives - Page 95 of 1818

TuesdayJan 24, 2012 11:41 am

Rainbow Coral Corp. (RBCC) to Engage Investment Banking Firm for Acquisition of Nano3D Biosciences

Yesterday, Rainbow Coral Corp. announces its search for a capable investment banking firm to assist in procuring capital for the acquisition of Nano3D Biosciences (n3D) and other target companies. Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Celgene Corp. (NASDAQ:CELG), Cardinal Health, Inc. (NYSE:CAH), Abbott Laboratories (NYSE:ABT) and Affymax, Inc. (NASDAQ:AFFY). RBCC is in the process of short-listing an investment banking firm in Houston, home of the company’s biosciences division. RBCC aims to work with Houston firms due to the impressive performance of the area’s biotech sector. In fact, this month the…

TuesdayJan 24, 2012 11:36 am

Medical Care Technologies, Inc. (MDCE) Closes $130,000 Loan for Construction of New State of the Art Chinese Children’s Health and Wellness Center

Medical Care Technologies, Inc., a Nevada incorporated medical services and technology company with headquarters in Beijing, today announced the closing of a $130,000 loan agreement with a private company in Hong Kong to finance the completion and construction of its first children's health and wellness center in Dongguan, Guangdong Province, China. The unsecured loan has an annual interest rate of 12% for two years. This is the last stage in funding needed to complete the licensing process of Medical Care Technologies' Chinese subsidiary Teddyberry™ and Company. "Achieving financial close is a crucial step forward in securing this license to deliver…

MondayJan 23, 2012 5:03 pm

Amarantus BioSciences (AMBS) Inks License Agreement with Power3 (PWRM) for Parkinson’s Application

Amarantus Biosciences, Inc., a biotech company focused on developing a first-in-class disease–modifying therapeutic protein for the treatment of Parkinson’s disease, today announced it has signed an exclusive worldwide license agreement with Power3 Medical Products, Inc. for the NuroPro® Blood Test as it relates to Parkinson’s disease diagnosis. Per the initial one-year agreement, Amarantus has an exclusive license to develop, manufacture, have manufactured, use, market, sell and import medical devices and methods under the Power3 Parkinson’s Disease Intellectual Property (IP). Amarantus now also has an exclusive, royalty-free, fully paid-up worldwide license to Power3 know-how, patents and patent applications which relate to…

MondayJan 23, 2012 3:21 pm

Biostar Pharmaceuticals, Inc. (BSPM) Secures Key R&D Cooperation Agreement with Chinese Military Organization

Today, Biostar Pharmaceuticals, a leading provider of pharmaceuticals and health supplements, like the Company’s popular OTC offering for chronic hepatitis B (Xin AoXing Oleanolic Acid Capsule), reported special selection (at a January 8th ceremony) by the PLA’s Fourth Military Medical University (FMMU) for cooperation in ongoing research and product development activities. The FMMU has been a major force in the Chinese military medical landscape since its formation in 1954 (out of the 4th and 5th Military Medical Colleges), serving a vital role as one of only a handful of key institutions for training middle- to high-level medical personnel for the…

MondayJan 23, 2012 2:45 pm

PLC Systems (PLCSF) Treats First Patient in RenalGuard® Pivotal Trial

PLC Systems, Inc., a medical device company focused on innovative technologies for the cardiac and vascular markets, today announced it has completed the enrollment of the first patient in the CIN-RG trial designed to study the efficacy of its RenalGuard Therapy® and RenalGuard System™ for the prevention of Contrast-Induced Nephropathy (CIN). This achievement marks an important step toward obtaining U.S. Food and Drug Administration (FDA) approval to distribute RenalGuard® in the United States. "RenalGuard offers us the potential for a method to reduce the incidence of CIN while allowing me as an interventional cardiologist to focus on the catheterization without…

FridayJan 20, 2012 6:39 pm

Nexxus Lighting, Inc. (NEXS) Announces Full ENERGY STAR® Qualification for Two Array LED Light Bulbs

Nexxus Lighting Inc., a leader in high performance LED replacement light bulbs with its Array® Lighting line of products, today announced that the Array R30 3000K Flood and the 3000K Accent LED light bulbs can now be marketed with a life certification of 50,000 hours after receiving full ENERGY STAR qualification. In October of 2010, the bulbs earned the ENERGY STAR mark and now the final round of lumen maintenance testing demonstrates that each bulb will last the equivalent of 10 years when the lamp is on for twelve hours per day. "All of the Array LED bulbs are designed…

FridayJan 20, 2012 3:41 pm

La Jolla Pharmaceutical (LJPC) Announces Acquisition of Novel Therapeutic, Significant Management Changes

La Jolla Pharmaceutical Company, a biopharmaceutical company developing treatments to improve the outcome of patients with life-threatening diseases, today announced that it has acquired global development and commercialization rights to GCS-100, a novel therapeutic for cancer and chronic organ failure. GCS-100’s ongoing development as an anti-cancer and anti-fibrotic agent is supported by extensive preclinical and clinical investigation, including phase 1 and phase 2 clinical trials. La Jolla acquired GCS-100 from privately held Solana Therapeutics Inc. (Solana). In connection with the acquisition, former Solana CEO George F. Tidmarsh, M.D., Ph.D. will serve as La Jolla’s new president and CEO. “Having been…

FridayJan 20, 2012 3:39 pm

INVO Bioscience (IVOB) Achieves Major Milestone with Infertility Device, Expands Market Reach into Brazil

INVO Bioscience Inc., a medical device company focused on treatment options for patients diagnosed with infertility, today announced that the National Health Surveillance Agency (ANVISA) in Brazil has granted approval of the INVOcell for use as a Class II device, which will allow the sale of INVOcell in the Brazilian market. The approval marks a significant milestone in INVO’s history, and opens the door for INVO to tap into one of the largest markets and fastest growing economies in the world. “Approval in Brazil is a very important step in the success of INVOcell due to the strength of support…

FridayJan 20, 2012 3:27 pm

FieldPoint Petroleum Corp. (FPP) Provides Update on Production at New Mexico Field

FieldPoint Petroleum recently reported an update on the company’s oil and gas activities in New Mexico. FieldPoint Petroleum is involved with Cimarex Energy (XEC) on the East Lusk Federal 15 well #1 in Lea County, New Mexico. The well targeted the Bone Spring formation and was completed in December 2011 with initial production of 446 barrels of oil per day. FieldPoint Petroleum reported that the well produced 735 barrels of oil and 588,000 cubic feet of natural gas per day on January 17, 2012. The most recent production report from the operator of the well has production at 673 barrels…

FridayJan 20, 2012 3:16 pm

Take Technical Analysis to the Next Level with QuantShare

All investors, whether trading for the short-term or long-term, should have at least a basic understanding of technical analysis to maximize their profit potential while minimizing losses. Stock charts put everything in perspective by putting the forces of supply and demand into an observable picture. Many traders rely exclusively on a stock’s trading history to make their buy and sell decisions. Rather than researching the company’s current position and future growth prospects, they analyze hundreds of stock charts for certain patterns, converging moving averages, indicator signals and volume activity. QuantShare is an advanced trading software that offers a complete charting…

Site Search

Company Search

Category: QualityStocks Stock Newsletters